The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptinor doxorubicin.本發明提供以高親和力結合人類CSF-1R之人類抗體。本發明抗體因具有以下多功能性而具有優於業內已知抗體之顯著優勢:抑制CSF-1R之信號傳導、內化並誘導CSF-1R降解及在包括腫瘤、巨噬細胞及單核細胞在內之細胞中刺激ADCC。亦顯示,其單獨或與多西他賽(docetaxel)、紫杉醇(paclitaxel)、赫賽汀(Herceptin)或多柔比星(doxorubicin)組合時,可有效治療白血病、乳癌、子宮內膜癌及前列腺癌。
